TR200200768T2 - Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri - Google Patents

Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri

Info

Publication number
TR200200768T2
TR200200768T2 TR2002/00768T TR200200768T TR200200768T2 TR 200200768 T2 TR200200768 T2 TR 200200768T2 TR 2002/00768 T TR2002/00768 T TR 2002/00768T TR 200200768 T TR200200768 T TR 200200768T TR 200200768 T2 TR200200768 T2 TR 200200768T2
Authority
TR
Turkey
Prior art keywords
quinuclide
derivatives
compositions containing
new
drug compositions
Prior art date
Application number
TR2002/00768T
Other languages
English (en)
Turkish (tr)
Inventor
Fernandez Forner Dolors
Prat Quinones Maria
Antonia Buil Albero Maria
Original Assignee
Almirall-Prodesfarma, S.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8309225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200768(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall-Prodesfarma, S.A filed Critical Almirall-Prodesfarma, S.A
Publication of TR200200768T2 publication Critical patent/TR200200768T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2002/00768T 1999-07-14 2000-07-07 Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri TR200200768T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Publications (1)

Publication Number Publication Date
TR200200768T2 true TR200200768T2 (tr) 2002-07-22

Family

ID=8309225

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00768T TR200200768T2 (tr) 1999-07-14 2000-07-07 Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri

Country Status (39)

Country Link
US (16) US6750226B2 (h)
EP (1) EP1200431B3 (h)
JP (2) JP4030040B2 (h)
KR (3) KR100773844B1 (h)
CN (2) CN100451018C (h)
AR (1) AR029760A1 (h)
AT (1) ATE235492T1 (h)
AU (1) AU2005202144B2 (h)
BE (1) BE2013C001I2 (h)
BG (1) BG65565B1 (h)
BR (1) BRPI0012434B8 (h)
CA (1) CA2381165C (h)
CO (1) CO5200759A1 (h)
CY (1) CY2013001I1 (h)
CZ (1) CZ304292B6 (h)
DE (2) DE60001840T4 (h)
DK (1) DK1200431T6 (h)
EE (1) EE04915B3 (h)
EG (1) EG24066A (h)
ES (2) ES2165768B1 (h)
FR (1) FR13C0001I2 (h)
HK (1) HK1042487B (h)
HU (1) HU228594B1 (h)
IL (1) IL147533A0 (h)
LU (1) LU92132I2 (h)
MY (1) MY126959A (h)
NO (2) NO329484B3 (h)
PE (1) PE20010397A1 (h)
PL (1) PL204024B1 (h)
PT (1) PT1200431E (h)
RU (2) RU2264401C3 (h)
SI (1) SI1200431T1 (h)
SK (1) SK287480B6 (h)
TR (1) TR200200768T2 (h)
TW (1) TWI284644B (h)
UA (1) UA73509C2 (h)
UY (2) UY26244A1 (h)
WO (1) WO2001004118A2 (h)
ZA (1) ZA200200232B (h)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
HU230328B1 (hu) 2000-08-05 2016-02-29 Glaxo Group Ltd Gyulladásgátló szerként alkalmazható 6-alfa,9-alfa-difluor-17-alfa-(2-furanilkarbonil)oxi-11-béta-hidroxi-16-alfametil-3-oxo-androszta-1,4-dién-17-tiokarbonsav-S-fluormetil-észter
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
BR0215348A (pt) * 2001-12-20 2004-11-16 S A L V A T Lab Sa Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
US7405224B2 (en) 2002-01-31 2008-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
WO2004056810A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
DE602004021921D1 (de) 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
EP1644356A1 (en) 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
AR045913A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
PE20050711A1 (es) * 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
EP1651270B1 (en) * 2003-07-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising betamimetics and an anticholinergic
CN1829520A (zh) * 2003-07-29 2006-09-06 贝林格尔·英格海姆国际有限公司 抗胆碱能药和类固醇的联用药物及其在通过吸入治疗呼吸疾病中的用途
WO2005013993A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
CN101230062A (zh) * 2003-10-14 2008-07-30 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
EP1677796A4 (en) * 2003-10-17 2006-12-27 Glaxo Group Ltd MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1891974B1 (en) * 2004-05-31 2010-07-21 Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
DE602004018844D1 (de) * 2004-06-16 2009-02-12 Ranbaxy Lab Ltd Als antagonisten des muscarinrezeptors geeignete xanthinderivate
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP5281291B2 (ja) 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
TWI389690B (zh) 2005-03-25 2013-03-21 Glaxo Group Ltd 新穎化合物（一）
US20090298802A1 (en) 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
JP2009503101A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
US20100015061A1 (en) * 2006-01-06 2010-01-21 Boehringer Ingeheim International GmnH Pharmaceutical Compositions Based on Anticholinergics and Andolast
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
AU2007241343B2 (en) 2006-04-21 2011-09-01 Novartis Ag Purine derivatives for use as adenosin A2A receptor agonists
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
JP2009543658A (ja) * 2006-07-14 2009-12-10 アストラゼネカ・アクチエボラーグ 乾燥粉末状の薬を投与するための吸入装置及び配送装置
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0622827D0 (en) 2006-11-15 2006-12-27 Glaxo Group Ltd Sheet driver for use in a drug dispenser
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
HRP20110201T1 (hr) 2007-01-10 2011-08-31 Irm Llc Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
MY153408A (en) * 2007-02-21 2015-02-13 Almirall Sa Novel methods
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
SI2197841T1 (sl) 2007-09-07 2012-02-29 Theravance Inc Spojine, ki vsebujejo gvanidin, uporabne kot antagonisti muskarinskih receptorjev
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2444120B1 (en) 2007-12-10 2017-09-27 Novartis AG Spirocyclic amiloride analogues as ENac blockers
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100599A1 (en) † 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
CA2723981A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab New compounds 273
WO2010068311A1 (en) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor
EP2778156B8 (en) 2008-05-27 2017-02-22 AstraZeneca AB Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
CA2758100C (en) 2009-04-09 2017-08-29 Novartis Ag Process for preparing pyrrolidinium salts
TW201103892A (en) 2009-04-24 2011-02-01 Glaxo Group Ltd Compounds
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
TWI562992B (en) 2009-04-30 2016-12-21 Glaxo Group Ltd Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT3111927T (pt) 2009-05-29 2020-03-03 Pearl Therapeutics Inc Composições para administração respiratória de agentes ativos e métodos e sistemas associados
GB0910537D0 (en) 2009-06-18 2009-07-29 Ivax Pharmaceuticals Ireland Inhaler
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
ES2548036T3 (es) 2010-09-08 2015-10-13 Glaxosmithkline Intellectual Property Development Limited Polimorfos y sales de N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oxazol-2-il)-1H-indazol-6-il]-2-(metiloxi)-3-piridinil]metanosulfonamida
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
TW201439089A (zh) * 2012-12-05 2014-10-16 Chiesi Farma Spa 新穎化合物
PL2931275T3 (pl) 2012-12-17 2022-09-05 Almirall S.A. Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP3023424B1 (en) * 2013-07-13 2019-02-27 Beijing Shuobai Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN103755699A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一种2-羟基-2,2-二噻吩-2-基乙酸-1-氮杂二环[2,2,2]辛-3(r)-基酯制备方法
CN103755698A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一锅法制备阿地溴铵的工艺
CZ2014188A3 (cs) 2014-03-26 2015-10-07 Zentiva, K.S. Nové formy aclidinium chloridu a způsob jejich přípravy
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
EP3134395B1 (en) 2014-04-24 2018-01-31 Novartis AG Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
ES2761569T3 (es) 2014-04-24 2020-05-20 Novartis Ag Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
US10155755B2 (en) 2015-03-02 2018-12-18 Ltt Bio-Pharma Co., Ltd. Quinuclidine derivative
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
WO2016162878A1 (en) * 2015-04-04 2016-10-13 Harman Finochem Limited An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i
CZ2015257A3 (cs) 2015-04-16 2016-10-26 Zentiva, K.S. Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu
CN105085355B (zh) * 2015-06-25 2017-11-14 御盛隆堂药业有限责任公司 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201700727D0 (en) 2017-01-16 2017-03-01 Teva Pharma Inhalers and airflow adaptors therefor
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190076607A1 (en) 2017-09-13 2019-03-14 Lupin Atlantis Holdings Sa Inhaler and mesh for an inhaler
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
WO2019129801A1 (en) 2017-12-28 2019-07-04 Linnea S.A. Process for the purification of methyl-2,2-dithienylglycolate
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
CR20220060A (es) 2019-08-28 2022-03-01 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
IL296794A (en) 2020-03-25 2022-11-01 Lupin Inc Multi-carrier medicament dispensers
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
CN116210004A (zh) 2020-07-23 2023-06-02 鲁平股份有限公司 用于药剂分配器的剂量计数器组件

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8718345D0 (en) * 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE69132735T2 (de) 1990-09-06 2002-05-29 Pfizer Inc., New York Anti-muscarin bronchodilatoren
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
ATE209938T1 (de) 1990-09-26 2001-12-15 Pharmachemie Bv Wirbelkammer-pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5263480A (en) 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
CA2151383C (en) 1992-12-09 2005-02-08 Paul Donald Jager Stabilized medicinal aerosol solution formulation
DK0674533T3 (da) 1992-12-18 1999-09-27 Schering Corp Inhalator for medikamenter i pulverform
HUT76289A (en) 1994-02-10 1997-07-28 Yamanouchi Pharma Co Ltd Carbamate derivative and medicinal composition containing the same
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) * 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
CA2196169A1 (en) 1994-07-29 1996-02-15 Greggory S. Bennett Acrylic syrup curable to a crosslinked viscoelastomeric material
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2206572T3 (es) 1995-04-14 2004-05-16 Smithkline Beecham Corporation Inhalador de dosis medida para salmeterol.
WO1997000703A1 (en) 1995-06-21 1997-01-09 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
AU6392496A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
DK1087750T3 (da) 1998-06-18 2004-01-26 Boehringer Ingelheim Pharma Farmaceutiske formuleringer til aerosoler med to eller flere aktive stoffer
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
HUP0204271A3 (en) 2000-01-31 2003-07-28 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of pde4 isozymes, pharmaceutical compositions containing them and their use
DE60125026T2 (de) 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6777132B2 (en) 2000-04-27 2004-08-17 Valence Technology, Inc. Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
HRP20021025B1 (hr) 2000-05-22 2013-11-22 Chiesi Farmaceutici S.P.A. Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
AU2002210575A1 (en) 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020122773A1 (en) 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020151541A1 (en) 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
DE10056104A1 (de) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
CN1250545C (zh) 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
SK14312003A3 (sk) 2001-05-25 2004-08-03 Pfizer Inc. Inhibítor PDE4 a anticholinergné činidlo v kombinácii na liečbu obštrukčných chorôb dýchacích ciest
MXPA03010791A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
CA2459493C (en) 2001-09-14 2011-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions for inhalation
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US20050152846A1 (en) 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PL219032B1 (pl) 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006508996A (ja) 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト 悪液質の治療における使用のための、ｐｄｅ４及びｐｄｅ３／４インヒビター
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
ATE384529T1 (de) 2003-03-28 2008-02-15 Nycomed Gmbh Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
WO2004084897A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
EP1651270B1 (en) 2003-07-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
CN1829520A (zh) 2003-07-29 2006-09-06 贝林格尔·英格海姆国际有限公司 抗胆碱能药和类固醇的联用药物及其在通过吸入治疗呼吸疾病中的用途
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
WO2005013993A1 (en) 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050025718A1 (en) 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE526967T1 (de) 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
HRP20120286T1 (hr) 2004-02-06 2012-04-30 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
NZ548302A (en) 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
DK1713473T3 (da) 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
US7712077B2 (en) * 2004-02-27 2010-05-04 International Business Machines Corporation Method and system for instantiating components conforming to the “COM” specification in custom contexts
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1891974B1 (en) 2004-05-31 2010-07-21 Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
US20090298802A1 (en) 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
KR20090121338A (ko) 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
MY153408A (en) 2007-02-21 2015-02-13 Almirall Sa Novel methods
EP2165159B1 (en) 2007-07-03 2013-07-17 Nxp B.V. Calibration of an amr sensor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
PL2931275T3 (pl) 2012-12-17 2022-09-05 Almirall S.A. Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc

Also Published As

Publication number Publication date
KR100773844B1 (ko) 2007-11-06
US20130310353A1 (en) 2013-11-21
ATE235492T1 (de) 2003-04-15
AU6433000A (en) 2001-01-30
IL147533A0 (en) 2002-08-14
US8802699B2 (en) 2014-08-12
US20190183867A1 (en) 2019-06-20
DE60001840D1 (de) 2003-04-30
US10588895B2 (en) 2020-03-17
BE2013C001I2 (h) 2019-05-21
AU2005202144A1 (en) 2005-06-09
CA2381165F (en) 2001-01-18
US20150246026A1 (en) 2015-09-03
FR13C0001I1 (h) 2013-01-03
UY26244A1 (es) 2000-12-29
PL357160A1 (en) 2004-07-12
US7750023B2 (en) 2010-07-06
EE04915B1 (et) 2007-10-15
US7897617B2 (en) 2011-03-01
DE60001840T4 (de) 2015-11-26
NO329484B1 (no) 2010-10-25
NO20020180D0 (no) 2002-01-14
DK1200431T3 (da) 2003-07-21
KR20020021155A (ko) 2002-03-18
HUP0202100A2 (en) 2002-10-28
CN1373760A (zh) 2002-10-09
HU228594B1 (en) 2013-04-29
BG65565B1 (bg) 2008-12-30
CY2013001I2 (el) 2015-10-07
US7078412B2 (en) 2006-07-18
DE60001840T3 (de) 2015-10-08
PL204024B1 (pl) 2009-12-31
ZA200200232B (en) 2003-04-10
ES2165768B1 (es) 2003-04-01
DK1200431T6 (en) 2015-09-28
US20100234333A1 (en) 2010-09-16
US9056100B2 (en) 2015-06-16
DE60001840T2 (de) 2003-12-11
JP4030040B2 (ja) 2008-01-09
BG106301A (en) 2002-08-30
JP2005350476A (ja) 2005-12-22
EE200200017A (et) 2003-04-15
KR20070007396A (ko) 2007-01-15
KR20070009744A (ko) 2007-01-18
US20030055080A1 (en) 2003-03-20
EE04915B3 (et) 2016-07-15
USRE46417E1 (en) 2017-05-30
LU92132I2 (fr) 2013-03-18
US20160296503A1 (en) 2016-10-13
US8513279B2 (en) 2013-08-20
DK1200431T5 (da) 2005-01-31
EP1200431A2 (en) 2002-05-02
US20080221155A1 (en) 2008-09-11
EP1200431B3 (en) 2015-06-24
RU2264401C3 (ru) 2018-06-01
US20170319557A1 (en) 2017-11-09
US20040132768A1 (en) 2004-07-08
NO2013002I2 (no) 2013-09-09
MY126959A (en) 2006-11-30
RU2005121162A (ru) 2007-01-20
BRPI0012434B8 (pt) 2021-05-25
US8129405B2 (en) 2012-03-06
CN100451018C (zh) 2009-01-14
CA2381165C (en) 2009-10-27
AU2005202144B2 (en) 2007-06-14
WO2001004118A3 (en) 2001-07-19
US20110118223A1 (en) 2011-05-19
US9687478B2 (en) 2017-06-27
US7196098B2 (en) 2007-03-27
HUP0202100A3 (en) 2003-09-29
US7109210B2 (en) 2006-09-19
SI1200431T1 (en) 2003-10-31
CN1272334C (zh) 2006-08-30
ES2165768A1 (es) 2002-03-16
CZ2002121A3 (cs) 2002-11-13
JP2003504368A (ja) 2003-02-04
KR100854315B1 (ko) 2008-08-26
RU2264401C2 (ru) 2005-11-20
EP1200431B1 (en) 2003-03-26
JP4951217B2 (ja) 2012-06-13
US20120122826A1 (en) 2012-05-17
ES2193098T3 (es) 2003-11-01
US6750226B2 (en) 2004-06-15
BRPI0012434B1 (pt) 2016-03-22
TWI284644B (en) 2007-08-01
PT1200431E (pt) 2003-07-31
RU2306312C2 (ru) 2007-09-20
CA2381165A1 (en) 2001-01-18
KR100854321B1 (ko) 2008-08-26
US10034867B2 (en) 2018-07-31
WO2001004118A2 (en) 2001-01-18
AR029760A1 (es) 2003-07-16
NO20020180L (no) 2002-03-13
ES2193098T7 (es) 2012-12-13
NO2013002I1 (no) 2013-02-11
EG24066A (en) 2008-05-08
CY2013001I1 (el) 2015-10-07
UA73509C2 (uk) 2005-08-15
US9333195B2 (en) 2016-05-10
HK1042487B (en) 2003-07-18
US20140303126A1 (en) 2014-10-09
PE20010397A1 (es) 2001-04-11
CZ304292B6 (cs) 2014-02-19
NO329484B3 (no) 2013-04-29
UY33494A (es) 2013-04-05
CN1824664A (zh) 2006-08-30
US20060106056A1 (en) 2006-05-18
SK287480B6 (sk) 2010-11-08
US20070099953A1 (en) 2007-05-03
US20050209272A1 (en) 2005-09-22
BR0012434A (pt) 2002-04-02
US7358260B2 (en) 2008-04-15
AU779881B2 (en) 2005-02-17
CO5200759A1 (es) 2002-09-27
FR13C0001I2 (fr) 2013-11-01
SK432002A3 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
TR200200768T2 (tr) Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
TR200101412T2 (tr) Yeni bileşikler.
DK1200412T3 (da) Antiproliferative imidazolforbindelser
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
TR200102928T2 (tr) Farmasötik bileşikler.
PL337499A1 (en) Novel 2-(iminomethyl)aminophenylic derivatives, their production and application as drugs and pharmaceutic agents containing such derivatives
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE231872T1 (de) Thiazolopyrimidinderivate
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
ES2243579T3 (es) Derivados de pirazolopirideno.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE398630T1 (de) Zyklische conotoxin-peptide
SE9902765D0 (sv) Novel compounds
PT1060175E (pt) Inibidores de triptase
SE9901077D0 (sv) Novel use
SE9804212D0 (sv) Compounds
TR200100455T2 (tr) Nimesulid içeren topikal farmasötik bileşimler
SE9801494D0 (sv) Novel use
SE9902551D0 (sv) Novel compounds
DK1355906T3 (da) 2H-1-benzopyranderivater, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados